Movetis discovers and commercializes orally bioavailable small‑molecule inhibitors that selectively block validated oncogenic drivers, using structure‑based design and integrated biomarker strategies. The company advances candidates through preclinical ADME/Tox optimization and adaptive early‑stage clinical programs to enable precision oncology treatments. Its assets are targeted at oncology providers and pharmaceutical partners for co‑development or licensing.
Funding
$63.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ELFounders
Product
Problem
Many cancer patients receive cytotoxic chemotherapy that lacks specificity, leading to limited efficacy, significant toxicity, and resistance in tumors driven by distinct molecular alterations. The absence of targeted small‑molecule agents for certain oncogenic pathways leaves unmet medical needs across multiple tumor types.
Solution
Movetis focuses on the discovery and commercialization of orally administered small‑molecule therapeutics that selectively inhibit validated oncogenic drivers. By leveraging structure‑based drug design, high‑throughput screening, and biomarker‑guided development, the company creates targeted therapies intended to block tumor‑specific signaling while sparing normal tissue. Preclinical programs are advanced through rigorous pharmacokinetic, pharmacodynamic, and safety profiling to generate clinical candidates that can be rapidly transitioned into Phase I/II trials. The pipeline emphasizes precision oncology approaches that align drug mechanisms with companion diagnostic markers, enabling personalized treatment regimens and potentially improving response rates and tolerability.
Target Audience
Primary customers are oncology healthcare providers and institutional oncology networks treating patients with molecularly defined cancers, as well as pharmaceutical partners seeking co‑development or licensing of targeted small‑molecule assets.
Features
- Structure‑based design of kinase and protein‑protein interaction inhibitors with sub‑nanomolar potency against defined oncogenic targets
- Oral formulation optimized for high bioavailability and predictable exposure across patient populations
- Integrated biomarker strategy linking companion diagnostics to patient selection and trial enrichment
- Proprietary ADME/Tox platform that accelerates lead optimization and de‑risking of clinical candidates
- Scalable GMP manufacturing process ensuring consistent purity and batch‑to‑batch reproducibility
- Early‑stage clinical development framework that includes adaptive trial designs and real‑time pharmacodynamic monitoring
- Intellectual property portfolio covering core scaffolds, synthesis routes, and formulation patents